CA-BELKIN
Belkin , a consumer electronics leader, today announced the revamped BOOSTCHARGE PRO 3-in-1 Wireless Charging Stand upgraded to support fast charging on Apple Watch Series 7, which charges from 0 to 80% in about 45 minutes, up to 33% faster than Series 6**. In a familiar form factor to the product launched in 2020, this upgraded version will deliver the same functionality to iPhone 13 and iPhone 12 models, AirPods Pro and AirPods with Wireless Charging Case.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005013/en/
Key features:
- Supports fast charging for Apple Watch Series 7
- "Made for MagSafe” engineered to provide up to 15W of charging power to iPhone 13 and iPhone 12 models***
- Provides 5W charging power for AirPods Pro and AirPods with Wireless Charging Case
- MagSafe stand for iPhone features a non-slip design to support iPhone 13 or iPhone 12 models in portrait or landscape mode and is compatible with MagSafe cases up to 3mm thick
- Includes 2-year warranty and Belkin Connected Equipment Warranty up to $2,500
- Includes 40W power supply unit
AVAILABILITY AND PRICING
Available in Apple stores (Americas and Asia) in June
Available in Apple stores (EMEA and Australia / New Zealand) in July
Available in retail stores around the world in the coming months.
MSRP $149.95 USD
IMAGERY
Images of all products are available for download HERE .
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity and audio solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people through technology whether at home, at work or on a new adventure. In 2018, Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remains forever inspired by people and the planet we live on.
© 2022 Belkin International, Inc. and/or its affiliates. All rights reserved.
All product names, logos, and brands are property of their respective owners.
_____________________________________
* Fast charging is only compatible with Apple Watch Series 7. Other models will have regular charge times.
** Based on testing conducted by Belkin in October 2021 using Apple Watch Series 7 (GPS) 45mm Aluminum with Sport band and Apple Watch Series 6 44mm Aluminum with Sport band (GPS), all devices tested with watchOS 8.0.1 software, Belkin BOOSTCHARGE PRO Portable Fast Charger for Apple Watch/Belkin BOOSTCHARGE PRO 3-in-1 Wireless Charging Pad with MagSafe and Apple 20W USB-C Power Adapter (Model A2305). Charge time varies with region, settings, and environmental factors; actual results will vary.
*** For iPhone 13 mini and iPhone 12 mini, MagSafe charging delivers up to 12W of peak power delivery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model4.11.2025 16:48:00 CET | Press release
Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE)Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE)Synergistic Cytotoxicity: NaN and ABE together decreased cell proliferation by 60% in vitro, suggesting synergistic effectsNo Tumor Activity: Histology revealed no ki67 staining and increased necrosis in Zeta-BC-007-treated tumorsImmune Activation: Treated mice showed elevated macrophage infiltration and increased circulating monocytes Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Increased Survival in Nude Mice Inoculated with MCF7 Breast Cancer (BC) in the Mammary Fat-Pad Achieved via a Single Injection of a Lipid-like Hydrogel Emulsion Containing a New Molecular Entity (NME
A New Era Begins: Visionaries Unite to Shape the Next 50 Years of Tourism at TOURISE4.11.2025 16:35:00 CET | Press release
More than 120 global leaders will convene in Riyadh for the inaugural TOURISE Summit this November, bringing together the largest cross-sector gathering covering all industries that benefit from the trillion dollar tourism sector. From sports, entertainment, media, transport and aviation; representatives from government, business and non-profits will join Expedia, Google, Amadeus, Accor, Nikki Beach, Red Sea Global, Certares and the Public Investment Fund (PIF). From headline panels and visionary keynotes to fireside chats and immersive sessions, TOURISE will spotlight the forces transforming global tourism, and the ideas shaping what comes next for the future of tourism. Get ready to witness history in the making. Over three electrifying days, across two dynamic stages, more than 120 of the world’s most influential visionaries, change-makers, and industry pioneers will converge at the inaugural TOURISE Summit – the boldest global platform designed to unite governments, businesses, inv
Digital Access Reaches Four in Five People Worldwide, DCO’s DEN 2025 Finds4.11.2025 16:35:00 CET | Press release
The Digital Cooperation Organization (DCO), the international organization dedicated to advancing inclusive and sustainable digital economies, today launched the Digital Economy Navigator (DEN) 2025 at the Second World Summit for Social Development (WSSD2) in Doha. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104849013/en/ From left to right: H.E. Deemah AlYahya, Secretary General of the Digital Cooperation Organization - H.E. Imaan Sulaiman Ibrahim, Honorable Minister of Women Affairs and Social Development, Federal Republic of Nigeria - Alaa Abdulaal, Chief of Digital Economy Insight at the Digital Cooperation Organization. (Photo: AETOSWire) The second edition of the Navigator provides the most comprehensive analysis to date of global digital-economy maturity. Covering 80 countries representing 94 per cent of global GDP and 85 per cent of the world’s population, the report draws on 145 indicators and a survey of more
GEOLOG Unveils the KickMaster™ Flow-Meter Family for Extreme Well Conditions4.11.2025 16:33:00 CET | Press release
Patented instruments deliver reliable Flow-In/Flow-Out, density, and temperature data in high gas-cut and solids-laden muds for onshore and deepwater operations GEOLOG, the largest independent surface-logging company and a pioneer in applying AI to formation evaluation and automated drilling performance, today announced the immediate availability of KickMaster™, a patented family of flow meters engineered to provide accurate, real-time measurements in the most demanding drilling environments. Developed by GEOLOG’s in-house R&D team, KickMaster™ addresses long-standing challenges in measuring heterogeneous mud flows. The system delivers reliable flow, density, and temperature data during critical drilling events, enabling faster detection, better decision-making, and improved well control. Three engineered models for precise flow managementFlow-Out Meter - For standard and high-volume mud returns. Operates reliably with >40% gas in mud and introduces ~70% lower backpressure than typical
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium4.11.2025 16:04:00 CET | Press release
Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRIFirst-of-its-kind single intratumoral injection for MBC to the spineTreated lesions showed full bone regeneration with reconstitution of trabecular bone, and no skeletal related events; mean lesion defect volume decreased by 87.9% at day 180.Therapeutic spread extended to nearby non-treated lesions, also achieving complete response within the same vertebral body Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 10, 2025. The abstract
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom